Clinical EfficacyThe great efficacy achieved by the placebo patients who switched over to bexicaserin in the OLE should help put to rest any remaining questions about whether any differences in baseline characteristics between arms contributing to the PACIFIC results.
Market PotentialBexicaserin will likely quickly takeover much of the existing Fintepla market, and then expand this market substantially.
Regulatory MilestonesBexicaserin received Breakthrough Therapy designation from FDA for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older.